# **Tuberculosis surveillance and** monitoring in Europe 2019



World Health Organization REGIONAL OFFICE FOR EUROPE

## 2017 data

# Sweden

### Total population at 23 April 2018 by EUROSTAT: 9 995 153

#### TB case notifications, 2017

| Total number of cases                                       | 5          | 20      |  |
|---|------------|---------|--|
| Notification rate per 100000                                | !          | 5.2     |  |
| New <sup>a</sup> and relapses                               | 4          | 488     |  |
| New <sup>a</sup> and relapses notification rate per 100 000 | 1          | 4.9     |  |
| Pulmonary   | 324        | (62.3%) |  |
| of which microscopy-positive                                | 104        | (32.1%) |  |
| of which laboratory-confirmed                               | 287        | (88.6%) |  |
| Laboratory-confirmed TB cases                               | 424        | (81.5%) |  |
| Mean age of new native TB cases                             | 56.8 years |         |  |
| Mean age of new foreign TB cases                            | 35.0 years |         |  |
| Foreign origin of all TB cases                              | 468        | (90.0%) |  |
| New (not previously treated)                                | 484        | (93.1%) |  |
|   |            |         |  |

<sup>a</sup> Cases with unknown previous treatment included in new cases.

TB notification rates by treatment history, 2008-2017

# Drug resistance surveillance and TB/HIV coinfection, 2017

| Completeness of DRS data <sup>a</sup>                                   | Yes     |         |
|---|---------|---------|
| Completeness of HIV data <sup>b</sup>                                   | -       |         |
| Case-linked data reporting  | Yes     |         |
| Cases with DST results  | 422     | (99.5%) |
| Estimated RR-TB among notified<br>pulmonary cases<br>N, (best–low–high) | 13-5-20 |         |
| Pulmonary MDR-TB cases notified   | 9       | (3.2%)  |
| of which XDR-TB cases   | 0       | (0.0%)  |
| Notified MDR-TB   | 11      | (2.6%)  |
| of which XDR-TB cases   | 0       | (0.0%)  |
| TB cases tested for HIV   | -       | -       |
| HIV-positive TB cases   | -       | -       |
| of these on ART   | -       | -       |

National coverage 100% or culturing ≥ 90%, C+/all TB cases > 50%, DST done for C+ > 75%, EQA ≥ 95%.
<sup>b</sup> More than 50% of TB cases with reported HIV status.

## Treatment outcome monitoring

| Geographical<br>coverage      | Nat  | tional  |  |         |  |
|-------------------------------|--|---------|--|---------|--|
| Outcome cohort                | New culture positive<br>pulmonary TB cases<br>notified in 2016ª<br>Yes |         | All MDR-TB cases notified in 2015 <sup>b</sup> |         |  |
| Case-linked data<br>reporting |  |         |  |         |  |
| Cases notified                | 370  |         | 22   |         |  |
| Success                       | 326  | (88.1%) | 20   | (90.9%) |  |
| Died                          | 10   | (2.7%)  | 0  | (0.0%)  |  |
| Failed                        | 0  | (0.0%)  | 0  | (0.0%)  |  |
| Lost to follow-up             | 5  | (1.4%)  | 0  | (0.0%)  |  |
| Still on treatment            | 10   | (2.7%)  | 1  | (4.5%)  |  |
| Not evaluated                 | 19   | (5.1%)  | 1  | (4.5%)  |  |

<sup>a</sup> Treatment outcome as presented is treatment outcome after 12 months.
<sup>b</sup> Treatment outcome as presented is treatment outcome after 24 months.

45-64

2015

-> 64

2017


New and relapsed TB cases - notification rates by age group,

2011


2013

15-44


0-14



#### TB cases by geographical origin, 2008-2017



#### MDR-TB cases by previous treatment history, 2008–2017



## TB/HIV coinfection, 2008-2017

2009

Data not available

2008-2017

15

12


9 6

3

0

Cases / 100 000

# Treatment outcome, new culture-confirmed pulmonary TB cases,



Source: European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2019 – 2017 data. Stockholm: ECDC; 2019

© European Centre for Disease Prevention and Control/WHO Regional Office for Europe, 2019